Skip to main content
Top
Published in: Journal of Inflammation 1/2015

Open Access 01-12-2015 | Research

MicroRNA-181b regulates endotoxin tolerance by targeting IL-6 in macrophage RAW264.7 cells

Authors: Wenjun Zhang, Xiaojun Shen, Luyang Xie, Maoping Chu, Yanmei Ma

Published in: Journal of Inflammation | Issue 1/2015

Login to get access

Abstract

Interleukin 6 (IL-6) is a major pro-inflammatory cytokine and dysregulation of IL-6 is relevant to many inflammatory diseases. Endotoxin induced tolerance of IL-6 is an important mechanism to avoid the excessive immune reaction. But to date, the molecular mechanisms of endotoxin tolerance of IL-6 remain unclear. Here we reported that IL-6 secretion and microRNA-181b (miR-181b) expression were inversely correlated following LPS stimulation. We also demonstrated that miR-181b targeting the 3′-UTR of IL-6 transcripts and up-regulation of miR-181b was associated with NF-kB. We further demonstrated that up-regulation of miR-181b in response to LPS was required for inducing IL-6 tolerance in macrophage. Our results suggested that the post-transcriptional control mediated by miR-181b could be involved in fine tuning the critical level of IL-6 expression in endotoxin tolerance.
Literature
2.
go back to reference Stabel JR. Host responses to Mycobacterium avium subsp. paratuberculosis: a complex arsenal. Anim Health Res Rev. 2006;7:61–70.CrossRefPubMed Stabel JR. Host responses to Mycobacterium avium subsp. paratuberculosis: a complex arsenal. Anim Health Res Rev. 2006;7:61–70.CrossRefPubMed
3.
go back to reference Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine a2a receptors*. Annu Rev Immunol. 2004;22:657–82.CrossRefPubMed Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine a2a receptors*. Annu Rev Immunol. 2004;22:657–82.CrossRefPubMed
4.
go back to reference Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997;9:853–8.CrossRefPubMed Maes M, Bosmans E, De Jongh R, Kenis G, Vandoolaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997;9:853–8.CrossRefPubMed
5.
go back to reference Kinjyo I, Hanada T, Inagaki-Ohara K, Mori H, Aki D, Ohishi M, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 2002;17:583–91.CrossRefPubMed Kinjyo I, Hanada T, Inagaki-Ohara K, Mori H, Aki D, Ohishi M, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity. 2002;17:583–91.CrossRefPubMed
6.
go back to reference Tham DM, Wang Y-X, Rutledge JC. Modulation of vascular inflammation by PPARs. Drug News Perspect. 2003;16:109–16.CrossRefPubMed Tham DM, Wang Y-X, Rutledge JC. Modulation of vascular inflammation by PPARs. Drug News Perspect. 2003;16:109–16.CrossRefPubMed
7.
go back to reference Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, Kennedy K, et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature. 2006;441:173–8.CrossRefPubMed Gilchrist M, Thorsson V, Li B, Rust AG, Korb M, Kennedy K, et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature. 2006;441:173–8.CrossRefPubMed
8.
go back to reference Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351–79.CrossRefPubMed Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010;79:351–79.CrossRefPubMed
9.
go back to reference Lodish HF, Zhou B, Liu G, Chen C-Z. Micromanagement of the immune system by microRNAs. Nat Rev Immunol. 2008;8:120–30.CrossRefPubMed Lodish HF, Zhou B, Liu G, Chen C-Z. Micromanagement of the immune system by microRNAs. Nat Rev Immunol. 2008;8:120–30.CrossRefPubMed
10.
go back to reference Quinn EM, Wang J, Redmond HP. The emerging role of microRNA in regulation of endotoxin tolerance. J Leukoc Biol. 2012;91:721–7.CrossRefPubMed Quinn EM, Wang J, Redmond HP. The emerging role of microRNA in regulation of endotoxin tolerance. J Leukoc Biol. 2012;91:721–7.CrossRefPubMed
11.
go back to reference Su X, Qian C, Zhang Q, Hou J, Gu Y, Han Y, et al. miRNomes of haematopoietic stem cells and dendritic cells identify miR-30b as a regulator of Notch1. Nat Commun. 2013;4:2903.PubMedCentralPubMed Su X, Qian C, Zhang Q, Hou J, Gu Y, Han Y, et al. miRNomes of haematopoietic stem cells and dendritic cells identify miR-30b as a regulator of Notch1. Nat Commun. 2013;4:2903.PubMedCentralPubMed
12.
go back to reference El Gazzar M, McCall CE. MicroRNAs distinguish translational from transcriptional silencing during endotoxin tolerance. Journal of Biological Chemistry. 2010;285:20940–51.CrossRefPubMedCentralPubMed El Gazzar M, McCall CE. MicroRNAs distinguish translational from transcriptional silencing during endotoxin tolerance. Journal of Biological Chemistry. 2010;285:20940–51.CrossRefPubMedCentralPubMed
13.
go back to reference Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest. 2012;122:1973–90.PubMedCentralPubMed Sun X, Icli B, Wara AK, Belkin N, He S, Kobzik L, et al. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest. 2012;122:1973–90.PubMedCentralPubMed
14.
go back to reference Liu Y, Chen Q, Song Y, Lai L, Wang J, Yu H, et al. MicroRNA-98 negatively regulates IL-10 production and endotoxin tolerance in macrophages after LPS stimulation. FEBS Lett. 2011;585:1963–8.CrossRefPubMed Liu Y, Chen Q, Song Y, Lai L, Wang J, Yu H, et al. MicroRNA-98 negatively regulates IL-10 production and endotoxin tolerance in macrophages after LPS stimulation. FEBS Lett. 2011;585:1963–8.CrossRefPubMed
15.
go back to reference Li XC L, Li YJ. MicroRNA-146a and Human Disease. Scand J Immunol. 2011;71:227–31. Li XC L, Li YJ. MicroRNA-146a and Human Disease. Scand J Immunol. 2011;71:227–31.
16.
17.
go back to reference Bäckdahl L, Bushell A, Beck S. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int J Biochem Cell Biol. 2009;41:176–84.CrossRefPubMed Bäckdahl L, Bushell A, Beck S. Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation. Int J Biochem Cell Biol. 2009;41:176–84.CrossRefPubMed
18.
19.
go back to reference Wang Q, Fang CH, Hasselgren P-O. Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2001;281:R1013–23.PubMed Wang Q, Fang CH, Hasselgren P-O. Intestinal permeability is reduced and IL-10 levels are increased in septic IL-6 knockout mice. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2001;281:R1013–23.PubMed
20.
21.
go back to reference Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. Expression of Angiotensin II and Interleukin 6 in Human Coronary Atherosclerotic Plaques Potential Implications for Inflammation and Plaque Instability. Circulation. 2000;101:1372–8.CrossRefPubMed Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. Expression of Angiotensin II and Interleukin 6 in Human Coronary Atherosclerotic Plaques Potential Implications for Inflammation and Plaque Instability. Circulation. 2000;101:1372–8.CrossRefPubMed
23.
go back to reference Yamakawa Y, Sugita Y, Nagatani T, Takahashi S, Yamakawa T, Tanaka S-i, et al. Interleukin-6 (IL-6) in patients with Behçet’s disease. J Dermatol Sci. 1996;11:189–95.CrossRefPubMed Yamakawa Y, Sugita Y, Nagatani T, Takahashi S, Yamakawa T, Tanaka S-i, et al. Interleukin-6 (IL-6) in patients with Behçet’s disease. J Dermatol Sci. 1996;11:189–95.CrossRefPubMed
24.
go back to reference Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002;51:3391–9.CrossRefPubMed Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002;51:3391–9.CrossRefPubMed
25.
go back to reference Klein B, Zhang X-G, Lu Z-Y, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863–72.PubMed Klein B, Zhang X-G, Lu Z-Y, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863–72.PubMed
26.
go back to reference Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. Journal of Clinical Endocrinology & Metabolism. 2005;90:2522–30.CrossRef Alesci S, Martinez PE, Kelkar S, Ilias I, Ronsaville DS, Listwak SJ, et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. Journal of Clinical Endocrinology & Metabolism. 2005;90:2522–30.CrossRef
27.
go back to reference Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Laboratory investigation; a journal of technical methods and pathology. 1992;66:223–30.PubMed Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk B. Detection of interleukin-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer's disease patients. Laboratory investigation; a journal of technical methods and pathology. 1992;66:223–30.PubMed
28.
go back to reference Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate. 2000;42:239–42.CrossRefPubMed Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate. 2000;42:239–42.CrossRefPubMed
29.
go back to reference Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232–4.CrossRefPubMedCentralPubMed Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52:232–4.CrossRefPubMedCentralPubMed
30.
go back to reference Muto T, Okazaki IM, Yamada S, Tanaka Y, Kinoshita K, Muramatsu M, et al. Negative regulation of activation-induced cytidine deaminase in B cells. Proc Natl Acad Sci U S A. 2006;103:2752–7.CrossRefPubMedCentralPubMed Muto T, Okazaki IM, Yamada S, Tanaka Y, Kinoshita K, Muramatsu M, et al. Negative regulation of activation-induced cytidine deaminase in B cells. Proc Natl Acad Sci U S A. 2006;103:2752–7.CrossRefPubMedCentralPubMed
31.
go back to reference Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E, et al. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma. 2010;57:264–9.CrossRefPubMed Slaby O, Lakomy R, Fadrus P, Hrstka R, Kren L, Lzicarova E, et al. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma. 2010;57:264–9.CrossRefPubMed
32.
go back to reference Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood. 2011;118:3072–9.CrossRefPubMedCentralPubMed Visone R, Veronese A, Rassenti LZ, Balatti V, Pearl DK, Acunzo M, et al. miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood. 2011;118:3072–9.CrossRefPubMedCentralPubMed
33.
go back to reference Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W, et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer. 2010;46:1640–9.CrossRefPubMed Zhi F, Chen X, Wang S, Xia X, Shi Y, Guan W, et al. The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma. Eur J Cancer. 2010;46:1640–9.CrossRefPubMed
34.
go back to reference Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z, et al. hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008;1236:185–93.CrossRefPubMed Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z, et al. hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008;1236:185–93.CrossRefPubMed
35.
go back to reference Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010;127:2520–9.CrossRefPubMed Zhu W, Shan X, Wang T, Shu Y, Liu P. miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer. 2010;127:2520–9.CrossRefPubMed
Metadata
Title
MicroRNA-181b regulates endotoxin tolerance by targeting IL-6 in macrophage RAW264.7 cells
Authors
Wenjun Zhang
Xiaojun Shen
Luyang Xie
Maoping Chu
Yanmei Ma
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2015
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/s12950-015-0061-8

Other articles of this Issue 1/2015

Journal of Inflammation 1/2015 Go to the issue